| __timestamp | Amphastar Pharmaceuticals, Inc. | AstraZeneca PLC |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 13324000000 |
| Thursday, January 1, 2015 | 46974000 | 11451000000 |
| Friday, January 1, 2016 | 47298000 | 9739000000 |
| Sunday, January 1, 2017 | 50918000 | 10543000000 |
| Monday, January 1, 2018 | 58044000 | 10362000000 |
| Tuesday, January 1, 2019 | 63109000 | 11848000000 |
| Wednesday, January 1, 2020 | 65157000 | 11693000000 |
| Friday, January 1, 2021 | 68920000 | 15680000000 |
| Saturday, January 1, 2022 | 66592000 | 18955000000 |
| Sunday, January 1, 2023 | 80393000 | 18025000000 |
| Monday, January 1, 2024 | 20532000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of AstraZeneca PLC and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, AstraZeneca's SG&A expenses have consistently dwarfed those of Amphastar, reflecting its larger scale and global reach. In 2023, AstraZeneca's expenses were approximately 22 times higher than Amphastar's, highlighting the stark contrast in their operational scales. However, Amphastar has shown a steady increase in its SG&A expenses, growing by nearly 99% over the decade, indicating its expanding operations. This trend underscores the dynamic nature of the pharmaceutical sector, where both giants and emerging players are constantly adapting to market demands.
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
AstraZeneca PLC or Bio-Techne Corporation: Who Manages SG&A Costs Better?
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.